Moderna shares plunge on apparent cancer vaccine data leak
Moderna shares dropped 25% and Merck fell 3% after preliminary cancer vaccine trial data was leaked. The data, later removed, showed a 42% risk reduction in melanoma recurrence or death when combining the vaccine with Keytruda. The Phase 3 trial involved 1,137 patients, with 82.2% of the combination group alive and cancer-free after two years.
How this was made
The 30-second read
Why it matters
The unexpected early release bypassed the usual controlled disclosure, amplifying uncertainty and prompting rapid price declines.
Market read
First public glimpse of Phase 3 data caused >25% drop in Moderna and >3% drop in Merck, highlighting material impact on biotech valuations.
What to watch
Regulatory pathway and pricing negotiations for the combo could mitigate short‑term price pressure.
Background
The leak occurred on a medical news site before the scheduled ESMO Congress presentation, prompting immediate market reaction.
Ticker impact
Moderna shares plunged >25% after an early leak of Phase 3 cancer‑vaccine trial results showing modest efficacy.
likely continued downward pressure as investors reassess the vaccine's value
First disclosure of trial efficacy; market reacted strongly and the stock fell 25%.
Merck fell >3% following the same leaked trial data indicating a 42% risk reduction when combined with its Keytruda drug.
potential further decline as analysts evaluate the commercial impact of the combination
Leak of detailed Phase 3 results is new information; market reacted negatively.
Market effects
Biotech sector may see broader risk reassessment of mRNA‑based cancer vaccines.
US biotech indices likely pressured; European peers may follow.
Large‑cap biotech stocks worldwide could experience volatility.
Counterpoint
If the combination therapy proves commercially viable, the sell‑off may be overblown.
Key entities
- CompanyModerna Inc.
Developer of the mRNA cancer vaccine.
- CompanyMerck & Co., Inc.
Provider of Keytruda immunotherapy.
